| Variable | Overall, N = 5,9751 | *Clinically Relevant Postoperative Pancreatic Fistula | p-value2 | |
|---|---|---|---|---|
| CR-POPF, N = 1,0181 | No CR-POPF, N = 4,9571 | |||
| PAN_FISTULA | <0.001 | |||
| Biochemical Leak | 77 (1.3%) | 0 (0%) | 77 (1.6%) | |
| ISGPS Grade B | 932 (16%) | 932 (92%) | 0 (0%) | |
| ISGPS Grade C | 86 (1.4%) | 86 (8.4%) | 0 (0%) | |
| No Fistula | 4,880 (82%) | 0 (0%) | 4,880 (98%) | |
| Age | 66.00 (58.00, 73.00) | 66.00 (58.00, 72.00) | 66.00 (58.00, 73.00) | 0.10 |
| SEX | <0.001 | |||
| female | 2,881 (48%) | 430 (42%) | 2,451 (49%) | |
| male | 3,094 (52%) | 588 (58%) | 2,506 (51%) | |
| BMI | 26.52 (23.33, 30.37) | 27.97 (24.67, 31.71) | 26.21 (23.08, 29.95) | <0.001 |
| RACE_NEW | 0.022 | |||
| Black | 499 (9.2%) | 63 (6.9%) | 436 (9.6%) | |
| Other | 303 (5.6%) | 46 (5.0%) | 257 (5.7%) | |
| White | 4,643 (85%) | 803 (88%) | 3,840 (85%) | |
| Unknown | 530 | 106 | 424 | |
| PAN_GLANDTEXT | <0.001 | |||
| Hard | 1,918 (40%) | 144 (17%) | 1,774 (44%) | |
| Intermediate | 580 (12%) | 80 (9.6%) | 500 (13%) | |
| Soft | 2,321 (48%) | 608 (73%) | 1,713 (43%) | |
| Unknown | 1,156 | 186 | 970 | |
| PAN_DUCTSIZE | <0.001 | |||
| <3 mm | 1,488 (30%) | 380 (44%) | 1,108 (27%) | |
| >6 mm | 752 (15%) | 73 (8.5%) | 679 (16%) | |
| 3-6 mm | 2,782 (55%) | 405 (47%) | 2,377 (57%) | |
| Unknown | 953 | 160 | 793 | |
| DIABETES | 1,572 (26%) | 215 (21%) | 1,357 (27%) | <0.001 |
| PAN_CHEMO | 1,032 (17%) | 102 (10%) | 930 (19%) | <0.001 |
| Unknown | 19 | 1 | 18 | |
| PAN_RADIO | 343 (5.8%) | 32 (3.1%) | 311 (6.3%) | <0.001 |
| Unknown | 24 | 2 | 22 | |
| PAN_MALIG_HISTOLOGIC | ||||
| Ampullary carcinoma | 478 (11%) | 119 (17%) | 359 (9.6%) | |
| Cystadenocarcinoma | 1 (<0.1%) | 0 (0%) | 1 (<0.1%) | |
| Distal cholangiocarcinoma | 167 (3.8%) | 42 (5.9%) | 125 (3.4%) | |
| Duodenal carcinoma | 126 (2.8%) | 24 (3.4%) | 102 (2.7%) | |
| IPMN-invasive | 121 (2.7%) | 21 (3.0%) | 100 (2.7%) | |
| Neuroendocrine-functioning | 58 (1.3%) | 23 (3.2%) | 35 (0.9%) | |
| Neuroendocrine-nonfunctioning | 306 (6.9%) | 89 (13%) | 217 (5.8%) | |
| Pancreatic adenocarcinoma | 3,181 (72%) | 392 (55%) | 2,789 (75%) | |
| Unknown | 1,537 | 308 | 1,229 | |
| ASACLAS | 0.53 | |||
| I-II | 1,316 (22%) | 216 (21%) | 1,100 (22%) | |
| III-IV | 4,656 (78%) | 801 (79%) | 3,855 (78%) | |
| Unknown | 3 | 1 | 2 | |
| DOpertoD | 86 (1.4%) | 21 (2.1%) | 65 (1.3%) | 0.091 |
| DPRBILI | 8.00 (4.00, 16.00) | 8.00 (4.00, 16.00) | 8.00 (4.00, 16.00) | 0.29 |
| Unknown | 226 | 41 | 185 | |
| SeriousComplication | 1,422 (24%) | 611 (60%) | 811 (16%) | <0.001 |
| AnyComplication | 1,672 (28%) | 652 (64%) | 1,020 (21%) | <0.001 |
| CPT | 0.36 | |||
| 48153 | 5,780 (97%) | 990 (97%) | 4,790 (97%) | |
| 48154 | 195 (3.3%) | 28 (2.8%) | 167 (3.4%) | |
| ChemoOnly | 708 (12%) | 70 (6.9%) | 638 (13%) | <0.001 |
| Unknown | 27 | 2 | 25 | |
|
1
Statistics presented: n (%); Median (IQR)
2
Statistical tests performed: chi-square test of independence; Wilcoxon rank-sum test
|
||||